A phase 2 study of mid-term compliance and effectiveness of dasatinib therapy in patients with chronic myeloid leukemia.
Phase 2
- Conditions
- Chronic myeloid leukemia chronic phase
- Registration Number
- JPRN-UMIN000007345
- Lead Sponsor
- Epidemiological and Clinical Research Information Network(ECRIN)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Pregnant and/or lactating woman 2. Other active neoplasms 3. History of sever bleeding tendency 4. Psychological disorders 5. Recent history of ischemic heart disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Compliance of dasatinib therapy at 12 months for patients with chronic myeloid leukemia.
- Secondary Outcome Measures
Name Time Method Treatment related toxicity (TRT) Relationship between serum concentration of Dasatinib and clinical result (TRT, Complete Cytogenetical remission rate,Major molecular Remission rate,Complete molecular remission) Overall survival rate at 1 year Progression free survival at 1 year
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie dasatinib's efficacy in chronic myeloid leukemia chronic phase patients in the DARIA 01 Trial?
How does dasatinib compare to imatinib in mid-term compliance and effectiveness for CML chronic phase patients in the DARIA 01 Trial?
What biomarkers are associated with response prediction to dasatinib therapy in the DARIA 01 Trial for CML chronic phase?
What adverse events were observed in the DARIA 01 Trial of dasatinib for chronic myeloid leukemia and how were they managed?
What are the implications of the DARIA 01 Trial for combination therapies involving dasatinib in chronic myeloid leukemia chronic phase?